GSK Signed a Multiyear Exclusive Collaborative Agreement with 23andMe to use Genetic Databases to Develop Novel Therapies.

 GSK Signed a Multiyear Exclusive Collaborative Agreement with 23andMe to use Genetic Databases to Develop Novel Therapies.

GSK Signed a Multiyear Exclusive Collaborative Agreement with 23andMe to use Genetic Databases to Develop Novel Therapies.

  Shots:
  •  With this collaboration GSK plans improve target selection to develop “Precision Medicine” with better efficacy and safety
  • To identify specific subgroups population to develop targeted treatments
  • GSK is initially planning to leverage 23andMe databases for the development of its   LRRK2i molecule in preclinical stage targeting Parkinson’s

Click here to read full press release/ article | Ref: GSK | Image: widdowquinn/Flickr

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post